🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Birmingham
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Birmingham

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 52 Manchester 17 Oxford 17 Cambridge 13 Birmingham 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Janssen Research & Development, LLC17 Merck Sharp & Dohme LLC16 Bristol-Myers Squibb14 Eli Lilly and Company14 Clear sponsor filter
Site city
London52 Manchester17 Oxford17 Cambridge13 Birmingham13
All 78 cities
Target enrolment
to
13 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
NCT06892522Multiple Myeloma
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport
2025-06-17
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
AbbVie
Phase 2
185
London, Oxford, Birmingham, Dundee
2024-12-13
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport
2023-11-15
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984Myelofibrosis (MF)
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
AbbVie
Phase 3
747
Bath, Warrington, London, Taunton, Prescot, Belfast, Birmingham, Dudley
2018-03-21
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
AbbVie
Phase 3
950
Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield
2017-01-31
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/birmingham

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.